Sunovion Knocks Out 5 Patents In Mylan's Brovana Suit

Law360, New York (March 02, 2012, 6:58 PM ET) -- Mylan Inc. on Friday vowed to appeal after a New York federal judge ruled that five patents asserted against Sunovion Pharmaceuticals Inc. in a suit over the chronic pulmonary obstructive disease drug Brovana were invalid, and limited potential damages on the two other patents-in-suit.

U.S. District Judge John Koeltl signed off on a 43-page opinion and order granting a motion for partial summary judgment from Dainippon Sumitomo Pharma Co. Ltd. unit Sunovion, concluding that the second of two families of patents being asserted by Mylan and...
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers